Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 14;40(4):989–1033. doi: 10.1007/s10555-021-10006-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A simplified summary of the main targetable metabolic pathways and related compounds. The schematic figure shows the main metabolic pathways and inhibitor therapy reported in different phase trials (marketed and tested drugs are labeled with green or red color, respectively). OXPHOS inhibitors, metformin (marketed in type 2 diabetes), fenofibrate (marketed in different cardiovascular diseases), atovaquone (marketed in malaria), arsenic trioxide (marketed in acute promyelocytic leukemia), mIBG (marketed in paraganglioma and pheochromocytoma), enasidenib mesylate (marketed in relapsed acute myeloid leukemia), leflunomide (marketed in psoriatic and rheumatoid arthritis), miltefosine (marketed in leishmaniasis), tetracycline, doxycycline, minocycline, tigecycline, azithromycin (marketed in bacterial infections), pyrvinium pamoate (FDA-approved anthelmintic drug) and drugs in clinical trials are vorasidenib (NCT04603001 — phase III in advanced hematologic malignancies), emvododstat (NCT03761069 — phase I in relapsed acute leukemias), FN-1501 (NCT03690154 — phase I in advanced solid tumors and leukemias), HMPL-306 (NCT04764474 — phase I in IDH gene mutated cancers), and SH-1573 — phase I in acute myelogenous leukemia); glycolysis inhibitors, nedosiran (NCT04042402 — phase III in primary hyperoxaluria), GP-2250 (NCT03854110 — phase II in pancreatic cancer), tuvatexib (NCT03538951 — phase II in actinic keratosis), PS101/3BP (NCT04021277 — phase I in hepatic metastases); lipid metabolism inhibitors, icosapent ethyl (marketed in different cardiovascular diseases), TVB-2640 (NCT03179904 — phase II in advanced breast cancers); glutaminolysis inhibitors, DRP-104 (NCT04471415 — phase II in advanced solid tumors), CB-839 (NCT03047993 — phase II in advanced myelodysplastic syndrome); transporter inhibitors, AZD-3965 (progressing to phase II trials), SLC-0111 (NCT03450018 — phase II in pancreatic ductal cancers), JPH-203 (pre-registration in bile-duct cancer)